ALK(SZ:002940) Xin Lang Cai Jing·2025-11-26 02:23Company Overview - Angli康 is a pharmaceutical company based in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company focuses on the research, production, and sales of chemical raw materials and formulations [1][2]. Financial Performance - For the period from January to September 2025, Angli康 reported a revenue of 1.055 billion yuan, a year-on-year decrease of 5.92%. However, the net profit attributable to shareholders increased by 55.59% to 77.6899 million yuan [2]. - The company has distributed a total of 360 million yuan in dividends since its A-share listing, with 128 million yuan distributed over the past three years [3]. Stock Performance - As of November 26, Angli康's stock price increased by 2.04% to 40.60 yuan per share, with a total market capitalization of 8.19 billion yuan. The stock has risen by 213.25% year-to-date, although it has seen a decline of 0.55% over the last five trading days [1]. - The stock has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) 15 times this year, with the most recent appearance on October 21, where it recorded a net buy of 15.2289 million yuan [1]. Shareholder Structure - As of September 30, 2025, Angli康 had 28,500 shareholders, an increase of 54.58% from the previous period. The average number of circulating shares per shareholder decreased by 35.31% to 6,493 shares [2]. - Notable institutional shareholders include 广发医疗保健股票A, 中欧医疗健康混合A, and several new entrants such as 汇添富创新医药混合A and 长城医药产业精选混合发起式A [3]. Industry Classification - Angli康 operates within the pharmaceutical and biotechnology sector, specifically in the chemical pharmaceutical and chemical formulation sub-industry. The company is associated with various concepts, including ursodeoxycholic acid, Helicobacter pylori, pet economy, hypertension prevention, and vitamins [2].